You are not logged in!
Do you want to login? It's free!

Wed, 16 April 2014.
Check the latest stories & news.

Search implu: Advanced

Who do you implu?    Create a Free Account!

Attachment 1

Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): October 29, 2008

 

 

Pharmasset, Inc.

(Exact Name of Issuer as Specified in Charter)

 

 

 

Delaware   001-33428   98-0406340

(State or Other Jurisdiction of

Incorporation or Organization)

  (Commission File Number)  

(I.R.S. Employer

Identification Number)

 

303-A College Road East

Princeton, New Jersey

  08540
(Address of Principal Executive Offices)   (Zip Code)

(609) 613-4000

(Registrant’s Telephone Number, Including Area Code)

 

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

 

 

 


Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers.

On October 29, 2008, the Board of Directors (the “Board”) of Pharmasset, Inc. (the “Company”) approved the Company’s fiscal 2009 Annual Performance Management Program (the “Bonus Plan”). The Bonus Plan is substantially similar to the fiscal 2008 Annual Performance Management Program described in the Company’s proxy statement filed with the Securities and Exchange Commission on January 25, 2008. Payouts under the Bonus Plan are subject to the Board’s discretion and are based on each participant’s performance as well as the achievement of certain corporate performance objectives. The Board approved the following corporate performance objectives for the Bonus Plan:

 

   

progress studies required for clevudine registration;

 

   

progress development of R7128 and PSI-7851;

 

   

continue research efforts to identify new product candidates; and

 

   

maintain an appropriate level of capitalization.

On October 29, 2008, the Board also approved the fiscal 2009 base salary and the potential amount that could be earned by each of the Company’s named executive officers participating in the Bonus Plan (expressed as a percentage of base salary) as set forth in the table below:

 

Name

  

Title

   Potential
Incentive
Compensation
   Fiscal 2009
Base Salary
P. Schaefer Price    President and Chief Executive Officer    30%    $ 455,000
Kurt Leutzinger    Chief Financial Officer    30%    $ 280,125
Michael J. Otto    Chief Scientific Officer    30%    $ 253,000
M. Michelle Berrey    Chief Medical Officer    30%    $ 288,500

On October 29, 2008, the Board also awarded bonus compensation to Messrs. Price, Leutzinger and Otto and Ms. Berrey under the fiscal 2008 Annual Performance Management Program. The amounts awarded to Messrs. Price and Otto and Ms. Berrey were in excess of their target levels under the fiscal 2008 Performance Management Program to reward them for exceeding certain corporate and individual objectives during fiscal 2008. The awarded amounts were paid to Messrs. Price, Leutzinger and Otto and Ms. Berrey on November 14, 2008 and were as follows:

 

Name

   Fiscal 2008
Bonus
Amount

P. Schaefer Price

   $ 135,000

Kurt Leutzinger

   $ 70,000

Michael J. Otto

   $ 90,000

M. Michelle Berrey

   $ 150,000


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    Pharmasset, Inc.
Date: January 22, 2009     By:  

/s/ Kurt Leutzinger

      Kurt Leutzinger
      Chief Financial Officer